. 2012 Aug 20;14(5):732–737. doi: 10.1038/aja.2012.57

Table 1. Patient clinical and characteristics.

Characteristics	Number of subjects	Median progression-free survival (month)	P value
Age at ketoconazole therapy, median 71 years (range 50–83 years)			0.213
<71 years	79	3.0
≥71 years	84	2.6
Clinical T stage			0.239
T2	66	3.0
T3–4	33	2.8
Unknown	64	2.0
Metastasis site			0.778
Lymph nodes only	10	3.0
Bone only	132	2.7
Lymph nodes and bone	16	2.6
Internal organ	5	2.8
Biopsy Gleason score			0.041
4–6	72	3.1
7	70	1.9
8–10	21	3.0
Nadir PSA			<0.001
<0.2 ng ml⁻¹	70	3.5
≥0.2 ng ml⁻¹	93	1.4
PSADT			0.025
<2.0 months	62	1.9
≥2.0 months	101	3.0
Baseline PSA			0.615
<20 ng ml⁻¹	76	2.8
≥20 ng ml⁻¹	87	2.6
Baseline testosterone			<0.001
<0.1 ng ml⁻¹	76	1.6
≥0.1 ng ml⁻¹	87	3.1
Baseline haemoglobin			0.004
Normal (≥120 g l⁻¹)	93	2.8
Less than normal	70	1.9
Baseline alkaline phosphatase			0.004
Normal (≤130 IU l⁻¹)	66	3.0
Greater than normal	97	1.9
Docetaxel chemotherapy			0.517
Yes	11	2.0
No	152	2.6

Abbreviations: PSA, prostate-specific antigen; PSADT, PSA doubling time.

The cutoffs for the nadir PSA and PSADT were based on the literature; the cutoffs for the baseline PSA and testosterone were based on the Youden index; the cutoffs for the baseline haemoglobin and alkaline phosphatase were the limiting value of the normal level.

The P value was calculated by the univariate Cox regression analysis.